Shivaani Kummar

Also affiliated with National Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Figshare(2023)10.1158/1078-0432.22487576.v1

Top 100%

0DataRank

Top 100%0 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Papers

Driven by 34 papers — median percentile 0. Top paper: “Targeting epigenetic abnormalities with histone deacetylase inhibitors”.

Targeting epigenetic abnormalities with histone deacetylase inhibitors

Cancer(2006)10.1002/cncr.22064

N/A

2.1DataRank · unranked

39 citations

John J. Wright, Shivaani Kummar, Barbara A. Conley

Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers

JCO Precision Oncology(2022)10.1200/po.21.00418

N/A

1.9DataRank · unranked

87 citations

Daniel S.W. Tan, Ulrik Lassen, Serge Leyvraz, Yongmei Liu, Jyoti D. Patel +10 more

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas

Cancer(2023)10.1002/cncr.35036

N/A

0.937DataRank · unranked

25 citations

Lin Shen, David S. Hong, Ray McDermott, Vicki L. Keedy, Michela Casanova +19 more

TRK Inhibition: A New Tumor-Agnostic Treatment Strategy

Targeted Oncology(2018)10.1007/s11523-018-0590-1

N/A

0.689DataRank · unranked

98 citations

Ulrik N. Lassen, Shivaani Kummar

Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas

Oncotarget(2020)10.18632/oncotarget.27784

N/A

0.457DataRank · unranked

20 citations

Shivaani Kummar, Robert Meehan, T. Khanh, Jerry M. Collins, Larry Anderson +20 more

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2145

N/A

0.416DataRank · unranked

15 citations

Naoko Takebe, Shivaani Kummar, Albiruni R. Abdul Razak, Sant P. Chawla, Suzanne George +13 more

Phase 1 study of Z-Endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors

Oncotarget(2021)10.18632/oncotarget.27887

N/A

0.360DataRank · unranked

10 citations

Geraldine O’Sullivan Coyne, Shivaani Kummar, Jerry M. Collins, Joel M. Reid, Richard Piekarz +18 more

Phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3088

N/A

0.358DataRank · unranked

5 citations

Geraldine O’Sullivan Coyne, Naoko Takebe, Abdul Rafeh Naqash, Jessica Mukherjee, Ashley Bruns +12 more

Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors

Cancer Chemotherapy and Pharmacology(2023)10.1007/s00280-023-04600-0

N/A

0.314DataRank · unranked

6 citations

Geraldine O’Sullivan Coyne, Jennifer Zlott, Shivaani Kummar, Robert Meehan, Larry Rubinstein +13 more

Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors

Investigational New Drugs(2021)10.1007/s10637-021-01138-x

N/A

0.312DataRank · unranked

7 citations

Apurva K. Srivastava, Tony Navas, Fabiola Cecchi, Young Ho Lee, Donald P. Bottaro +11 more

Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas

Cancer Chemotherapy and Pharmacology(2025)10.1007/s00280-025-04778-5

N/A

0.258DataRank · unranked

4 citations

Shivaani Kummar, Larry Rubinstein, Deborah Wilsker, Nancy Young Moore, Murielle Hogu +16 more

Evaluating the indotecan–neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal Emax regressions

Cancer Chemotherapy and Pharmacology(2023)10.1007/s00280-023-04509-8

N/A

0.104DataRank · unranked

1 citations

Benjamin C. Kennard, Julianne L. Holleran, Nancy Young Moore, Jennifer Zlott, Brian Miller +7 more

Increasing patient participation in oncology clinical trials

Cancer Medicine(2022)10.1002/cam4.5150

N/A

0DataRank · unranked

26 citations

Ying Lü, Shivaani Kummar, Jie Chen

Diagnosis and management of TRK fusion cancer

The American Journal of Managed Care(2022)10.37765/ajmc.2022.88834

N/A

0DataRank · unranked

7 citations

Shivaani Kummar

Extended progression-free survival and long-term safety of nirogacestat in patients with desmoid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11545

N/A

0DataRank · unranked

5 citations

Shivaani Kummar, Seth M. Steinberg, Murielle Hogu, Naoko Takebe, Amisha Shah +3 more

Safety, pharmacodynamic, and clinical response evaluation of nilotinib and paclitaxel in adults with refractory solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3026

N/A

0DataRank · unranked

1 citations

Geraldine O’Sullivan Coyne, Shivaani Kummar, Murielle Hogu, Larry Rubinstein, Sarah Miller +15 more

542P Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients

Annals of Oncology(2020)10.1016/j.annonc.2020.08.656

N/A

0DataRank · unranked

3 citations

David S. Hong, Andrew Briggs, Jesús García‐Foncillas, Ulrik Lassen, Gilles Vassal +9 more

Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3022

N/A

0DataRank · unranked

2 citations

Alice P. Chen, Shivaani Kummar, Murielle Hogu, Larry Rubinstein, Naoko Takebe +15 more

Data from Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer

(2023)10.1158/1078-0432.c.6519774.v1

N/A

0DataRank · unranked

0 citations

Austin G. Duffy, Shivaani Kummar, Nicole L. Simone, Yoshio Arai, Seungwon W. Kim +13 more

Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Figshare(2023)10.1158/1078-0432.22487576.v1

Top 100%

0DataRank

Top 100%0 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Data from Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells

(2023)10.1158/1078-0432.c.6519651

N/A

0DataRank · unranked

0 citations

Thomas D. Pfister, Ralph E. Parchment, Shivaani Kummar, Larry Rubinstein, Yvonne A. Evrard +6 more

Data from Phase 0 Trials: Expediting the Development of Chemoprevention Agents

(2023)10.1158/1940-6207.c.6544881

Top 100%

0DataRank

Top 100%0 citations

James H. Doroshow, Shivaani Kummar

The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers

Cancer Chemotherapy and Pharmacology(2024)10.1007/s00280-024-04651-x

N/A

0DataRank · unranked

1 citations

Naoko Takebe, Alice P. Chen, Shivaani Kummar, Richard Piekarz, Brian F. Kiesel +5 more

A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors

Cancer Chemotherapy and Pharmacology(2025)10.1007/s00280-025-04844-y

N/A

0DataRank · unranked

1 citations

Shivaani Kummar, Larry Rubinstein, Jennifer Zlott, Geraldine O’Sullivan Coyne, Vincent Chung +17 more

Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models

Frontiers in Oncology(2025)10.3389/fonc.2025.1571635

N/A

0DataRank · unranked

1 citations

Sergio Y. Alcoser, MICHAEL E. MULLENDORE, Li Chen, Chih-Jian Lih, Vishnuprabha Rahul Kannan +18 more

Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology(2020)10.1007/s00280-020-04073-5

N/A

0DataRank · unranked

26 citations

Lihua Wang, Jennifer Zlott, Lamin Juwara, Joseph M. Covey, Jan H. Beumer +18 more

Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3624

N/A

0DataRank · unranked

4 citations

Arjun Mittra, Geraldine O’Sullivan Coyne, Li Chen, Biswajit Das, Shivaani Kummar +15 more

Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1412

N/A

0DataRank · unranked

8 citations

Eric Laille, Ulka N. Vaishampayan, Vincent Chung, Karen Kelly, Afshin Dowlati +16 more

Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0329

N/A

0DataRank · unranked

71 citations

Abdul Rafeh Naqash, Geraldine O’Sullivan Coyne, Shivaani Kummar, T. Khanh, Ashley Bruns +19 more

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2480

N/A

0DataRank · unranked

27 citations

Shivaani Kummar, James Hu, Kristen Ganjoo, Warren A. Chow, Khanh T. Do +17 more

Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial

JCO Precision Oncology(2021)10.1200/po.20.00372

N/A

0DataRank · unranked

45 citations

Shivaani Kummar, Nancy Moore, Larry Rubinstein, Yingdong Zhao, P. Mickey Williams +20 more

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4256

N/A

0DataRank · unranked

98 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps3158

N/A

0DataRank · unranked

6 citations

María E. Suarez‐Almazor, Jeane Painter, Tanner M. Johanns, Michael Dougan, Laura C. Cappelli +15 more

A Novel Artificial Intelligence–Powered Method for Prediction of Early Recurrence of Prostate Cancer After Prostatectomy and Cancer Drivers

JCO Clinical Cancer Informatics(2022)10.1200/cci.21.00131

N/A

0DataRank · unranked

30 citations

Ramandeep S. Randhawa, Parag Jain, Samuel Hubbard, Jens C. Eickhoff, Shivaani Kummar +4 more

Shivaani Kummar

Indexed papers

Top data-sharing exemplar

Papers